Real-world data of 12-month adjunct sodium-glucose co-transporter-2 inhibitor treatment in type 1 diabetes from the German/Austrian DPV registry: Improved HbA1c without diabetic ketoacidosis

Diabetes Obes Metab. 2022 Apr;24(4):742-746. doi: 10.1111/dom.14620. Epub 2021 Dec 23.
No abstract available

Keywords: SGLT2 inhibitor; antidiabetic drug; population study; primary care; type 1 diabetes.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Austria
  • Diabetes Mellitus, Type 1* / complications
  • Diabetes Mellitus, Type 1* / drug therapy
  • Diabetic Ketoacidosis* / epidemiology
  • Diabetic Ketoacidosis* / prevention & control
  • Germany
  • Glucose
  • Glycated Hemoglobin
  • Humans
  • Hypoglycemic Agents / therapeutic use
  • Registries
  • Sodium
  • Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use
  • Symporters*

Substances

  • Glycated Hemoglobin A
  • Hypoglycemic Agents
  • Sodium-Glucose Transporter 2 Inhibitors
  • Symporters
  • Sodium
  • Glucose